Self-reported cognitive impairments and quality of life in patients with gastrointestinal stromal tumor: Results of a multinational survey.

Autor: Ferguson RJ; Biobehavioral Cancer Control Program, UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, USA.; Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA., Manculich J; Biobehavioral Cancer Control Program, UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, USA., Chang H; Biobehavioral Cancer Control Program, UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, USA., Sareen NJ; Biobehavioral Cancer Control Program, UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, USA.; Cancer Therapeutics Program, UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, USA., Snitz BE; Department of Neurology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA., Terhorst L; School of Health and Rehabilitation Sciences Data Center, University of Pittsburgh, Pittsburgh, Pennsylvania, USA., Bovbjerg DH; Biobehavioral Cancer Control Program, UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, USA.; Department of Psychiatry, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA., Duensing AU; Cancer Therapeutics Program, UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, USA.; Department of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
Jazyk: angličtina
Zdroj: Cancer [Cancer] 2022 Nov 15; Vol. 128 (22), pp. 4017-4026. Date of Electronic Publication: 2022 Sep 20.
DOI: 10.1002/cncr.34469
Abstrakt: Background: Cancer-related cognitive impairment (CRCI) has long-term effects on survivor quality of life, but CRCI research on patients with gastrointestinal stromal tumor (GIST) is lacking. The aims of this study were to investigate CRCI and concomitant quality of life among patients with GIST.
Methods: An online survey was used to assess CRCI in adult patients with GIST using the validated Functional Assessment of Cancer Therapy-Cognitive-v.3. Age, education, demographically indexed IQ, general health, and quality of life factors (e.g., fatigue, emotional distress) were also assessed. The online survey was administered through five international GIST and sarcoma support organizations.
Results: Over the 3-month recruitment period, the survey was completed by 485 participants: mean age, 57.80 (SD, 11.51), median 5 years after diagnosis. A majority (63.91%) reported experiencing cognitive symptoms with a significant negative quality of life impact. Controlling for age, patients with GIST ≥5 years after diagnosis reported worse cognitive function than those <5 years after diagnosis (p < .05) but did not differ in educational level or IQ. Whereas longer term survivors were more likely to have been treated with tyrosine kinase inhibitor (TKI) therapies, there was no observed association of TKI therapy with self-reported cognitive impairments.
Conclusions: A majority of GIST patients report cognitive symptoms that have a negative impact on quality of life, with longer term survivors (≥5 years) tending to report more cognitive impairments. Given the success of TKI therapy to substantially increase overall survival of patients with GIST, addressing CRCI in clinical practice may improve long-term GIST survivor function and quality of life.
(© 2022 The Authors. Cancer published by Wiley Periodicals LLC on behalf of American Cancer Society.)
Databáze: MEDLINE
Externí odkaz: